- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This study is testing a new drug, SY-1425, for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers are looking at how well it works, especially for patients with specific genetic markers, and if it's safe when used alone or with other medicines.
For: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
This study is testing a new drug (tamibarotene) alongside a standard treatment (azacitidine) for adults recently diagnosed with a specific type of higher-risk myelodysplastic syndrome (MDS). It aims to see if the new combination helps more patients achieve complete remission.
For: Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic SyndromeAustria · Poland · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy
This study looks at a new drug, tamibarotene, combined with venetoclax and azacitidine, for adults with a specific type of acute myeloid leukaemia (AML) who can't have standard treatment. It aims to see how safe the combination is and if it makes the cancer go into remission.
For: RARA-positive acute myeloid leukemiaFrance